BridgeBio Pharma (BBIO) Profit After Tax (QoQ) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.43% |
| Dec 31, 2025 | -5.24% |
| Sep 30, 2025 | -0.64% |
| Jun 30, 2025 | -8.34% |
| Mar 31, 2025 | 36.57% |
| Dec 31, 2024 | -62.79% |
| Sep 30, 2024 | -117.43% |
| Jun 30, 2024 | -108.92% |
| Mar 31, 2024 | 78.77% |
| Dec 31, 2023 | 5.10% |
| Sep 30, 2023 | -11.69% |
| Jun 30, 2023 | -12.59% |
| Mar 31, 2023 | -1.54% |
| Dec 31, 2022 | -0.27% |
| Sep 30, 2022 | -5,378.43% |
| Jun 30, 2022 | 98.73% |
| Mar 31, 2022 | -32.21% |
| Dec 31, 2021 | 5.42% |
| Sep 30, 2021 | -57.74% |
| Jun 30, 2021 | 40.34% |
| Mar 31, 2021 | -26.70% |
| Dec 31, 2020 | -3.73% |
| Sep 30, 2020 | 4.44% |
| Jun 30, 2020 | -30.87% |
| Mar 31, 2020 | -23.68% |
| Dec 31, 2019 | -38.72% |
| Sep 30, 2019 | -87,818.84% |
| Jun 30, 2019 | 99.90% |
| Mar 31, 2019 | -41.01% |
| Dec 31, 2018 | -17.02% |
| Sep 30, 2018 | -58.48% |